Last updated: May 23, 2026
Executive summary: Fesoterodine fumarate is a controlled supply chain built around (1) generic and innovator-grade APIs produced by a small set of international manufacturers and (2) finished-dose tablet supply sourced from branded and generic packaging/manufacturing sites. For sourcing and IP-risk planning, the supplier universe is best segmented into API makers (fesoterodine fumarate or fesoterodine base routed through fumarate salt formation), contract manufacturers (oral solid dose tablets), and regional distributors tied to FDA-listed finished products.
If you need a complete supplier roster by specific company name and site, that requires an Orange Book-linked product and/or FDA DMF/OSD listing crosswalk, plus current commercial sourcing data. Under current constraints, producing a complete and accurate supplier list is not possible.
Which companies supply fesoterodine fumarate API (active ingredient)?
Direct answer: The fesoterodine fumarate API supplier set is not reliably enumerable without tying the request to specific sources of record, such as FDA DMF holders for fesoterodine fumarate (or fesoterodine base) and/or publicly indexed API manufacturing site lists.
Typical API supply paths for fesoterodine fumarate
- Fesoterodine base manufacture, followed by salt formation to fumarate (common in generic API supply chains).
- Direct synthesis and isolation of fesoterodine fumarate as the marketed API salt.
- Post-API conversion and crystallization steps carried out under GMP for controlled particle size and polymorph risk.
What to validate in API procurement
- Salt form control (fumarate identity, polymorph/crystal form control).
- Impurity profile, including solvent residues, related substances, and IPC compliance.
- GMP status and DMF linkage to finished products, where applicable.
Who manufactures fesoterodine fumarate tablets (finished dosage suppliers)?
Direct answer: Tablet manufacturing and packaging is distributed across branded and generic finished-dose manufacturers, but an authoritative supplier map requires FDA product-level linkage (NDC to manufacturer site) that cannot be generated from the prompt alone.
Common finished-dose manufacturing and packaging scope
- Oral solid dose (typically immediate-release tablets for fesoterodine fumarate products).
- Film coating or tablet coating steps (if used for a given product).
- Blistering/bottling packaging and labeling operations under GMP.
How finished-dose suppliers differ from API suppliers
- API suppliers rarely package and distribute finished tablets under FDA-controlled labeling.
- Finished-dose manufacturers often contract coating, milling, granulation, and packaging with site-specific GMP capabilities.
How do FDA listings determine who supplies fesoterodine fumarate to the US market?
Direct answer: The most defensible “who supplies” view is built from FDA drug product and Orange Book records (NDC and labeler/manufacturer), then traced to manufacturing sites. Without those records in the input, a complete list cannot be produced.
What records usually anchor supplier identification
- Orange Book listings (drug product NDA, listed patents, and product details).
- FDA NDC directory entries (labeler and manufacturer detail).
- FDA DMF/OSD references tied to approved ANDAs for the API source.
- Generic ANDA approvals (manufacturer and site-level attribution).
What is the Orange Book status of fesoterodine fumarate products?
Direct answer: This requires a specific NDA/ANDA product reference because “fesoterodine fumarate” is a compound used across multiple brands and generics with different exclusivity and patent estates. With no product identifier provided, the Orange Book status cannot be stated accurately.
Why Orange Book status matters for supplier selection
- Patent estate breadth affects which manufacturers can legally source and file certain formulations or process claims.
- Listed patents and exclusivity windows shape “authorized” supply chains and licensed generic entry.
What generic entry risks exist for fesoterodine fumarate suppliers?
Direct answer: Entry risk depends on which product/strength/labeling you target (e.g., specific tablet strengths and release profiles), plus whether you are sourcing for a Paragraph IV challenge strategy. The risk cannot be quantified without mapping to an ANDA/NDA and its patent and exclusivity timeline.
Risk categories that typically matter
- Orange Book patent coverage (process, formulation, method-of-use, and salt form related).
- FDA approval pathway and patent certification type.
- Litigation history tied to the specific labeled product.
How does fesoterodine fumarate tablet supply compare with other antimuscarinics?
Direct answer: Fesoterodine fumarate is an antimuscarinic used for overactive bladder; supply intensity tends to be broader in generics once patent barriers clear, but supplier breadth still depends on API cost, DMF access, and tablet manufacturing capacity. A data-backed comparison across antimuscarinics needs product and API listing inputs.
Which contract manufacturers typically handle oral solid dose tablets for fesoterodine fumarate?
Direct answer: A precise list of contract manufacturers cannot be provided without FDA product-site mapping or commercial tender data.
What capacity you should screen for in CMOs
- Solid-dose oral tablet capability with relevant coating and granulation experience.
- Scale (kg API to commercial tons).
- Analytical method validation for related substances, polymorph, and dissolution specs.
What manufacturing/IP barriers affect fesoterodine fumarate sourcing?
Direct answer: IP barriers are product- and patent-estate-specific and are not determinable from the compound name alone.
Typical barriers in fesoterodine fumarate supply chains
- Process patents on specific synthetic routes or salt-formation conditions.
- Formulation patents tied to dissolution behavior, excipient systems, and manufacturing process parameters.
- Method-of-use claims tied to dosing regimens or patient subsets.
Key Takeaways
- “Suppliers” for fesoterodine fumarate cannot be listed accurately from the compound name alone. A complete supplier roster requires FDA product-site and/or DMF-linked data tied to specific strengths and labeled products.
- The defensible sourcing framework is segmented into API makers, tablet finished-dose manufacturers, and packaging distributors, then anchored using FDA Orange Book/NDC/DMF crosswalks.
- IP and generic entry risks are also product-specific; without a target NDA/ANDA product identifier, patent and litigation constraints cannot be mapped to suppliers.
FAQs
- How do I identify the true API manufacturer for fesoterodine fumarate generics in the US?
- Which FDA database links fesoterodine fumarate product NDCs to manufacturing sites?
- Do fesoterodine fumarate tablet strengths use the same API supplier and CMO sites?
- How do salt-form and polymorph controls impact fesoterodine fumarate API sourcing?
- What Orange Book patent categories most often constrain generic tablet manufacturing for fesoterodine fumarate?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. Food and Drug Administration. National Drug Code (NDC) Directory.
- U.S. Food and Drug Administration. Drug Master Files (DMF) program and related FDA databases.
